Background An increased risk of thrombosis has been reported in primary immune
thrombocytopenia (ITP) and with the use of thrombopoietin (TPO) receptor agonists, on the …

In primary chronic immune thrombocytopenia, long‐term response to splenectomy, with 60%
of patients enjoying a treatment‐free life, is higher when compared with rituximab and …

Introduction Primary immune thrombocytopenia (ITP) is an autoimmune disorder
characterized by a low platelet count (< 100× 109/L) with an increased risk of bleeding …

Chronic primary immune thrombocytopenia (ITP) can today benefit from multiple therapeutic
approaches with proven clinical efficacy, including rituximab, thrombopoietin receptor …

Primary immune thrombocytopenia (ITP) is a bleeding disorder commonly encountered in
clinical practice. The International Working Group (IWG) on ITP has published several …

Adults with newly diagnosed or persistent immunothrombocytopenia frequently relapse
upon tapering steroids; adults and children with chronic disease have an even lower …

Refractory immune thrombocytopenia (ITP) was previously defined as lack of a minimum
response to splenectomy and the requirement for long-term treatment to reduce the risk of …

Splenectomy, while often necessary in otherwise healthy patients after major trauma, finds
its primary indication for patients with underlying malignant or nonmalignant hematologic …

专家简介: 侯明, 山东大学齐鲁医院肿瘤中心主任, 血液科主任, 山东省血液免疫重点实验室主任,
泰山学者, 山东大学二级教授, 博士生导师. ITP 国际工作组指南制定专家组成员, ASH 资深会员 …

Approximately 80% of adult patients with immune thrombocytopenia (ITP) have treatment
failure with corticosteroids or become dependent on them and require second-line therapy …